Cargando…

Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats

BACKGROUND: Salvianolate lyophilized injection (SLI) has been clinically used in China for the treatment of acutely cerebral infarction. Clinical and experimental studies have shown that Diabetes mellitus (DM) not only increases the risk of ischemic stroke recurrence but also leads to poor outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fujiang, He, Qiansong, Wang, Jinxin, Yuan, Qing, Guo, Hong, Chai, Lijuan, Wang, Shaoxia, Hu, Limin, Zhang, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424323/
https://www.ncbi.nlm.nih.gov/pubmed/28486941
http://dx.doi.org/10.1186/s12906-017-1738-8
_version_ 1783235108434608128
author Wang, Fujiang
He, Qiansong
Wang, Jinxin
Yuan, Qing
Guo, Hong
Chai, Lijuan
Wang, Shaoxia
Hu, Limin
Zhang, Yue
author_facet Wang, Fujiang
He, Qiansong
Wang, Jinxin
Yuan, Qing
Guo, Hong
Chai, Lijuan
Wang, Shaoxia
Hu, Limin
Zhang, Yue
author_sort Wang, Fujiang
collection PubMed
description BACKGROUND: Salvianolate lyophilized injection (SLI) has been clinically used in China for the treatment of acutely cerebral infarction. Clinical and experimental studies have shown that Diabetes mellitus (DM) not only increases the risk of ischemic stroke recurrence but also leads to poor outcomes and increases fatality rates after stroke. Our previous study has proved that SLI can reduce the infarct volume after stroke in type 1 diabetic rats. The aim of the study is to explore the mechanism of SLI on stroke outcome in type 1 diabetic (T1DM) rats. METHODS: Type 1 diabetes rats model (T1DM) was induced in male Wistar rats by intraperitoneal (i.p) injection of streptozotocin (60 mg/kg) and T1DM rats were subjected to intraluminal middle cerebral artery occlusion (MCAO). The T1DM + MCAO rats were randomly divided into six groups: sham-operated, model-vehicle, positive control group (Edaravone-treating, DE 6 mg/kg) and SLI-treating group (10.5 mg/kg, 21 mg/kg and 42 mg/kg). SLI and DE were administered by tail vein injection at 3 h after MCAO, then daily for 14 days. Micro-CT scans of the brain tissue revealed vessel characteristics and distribution in the ischemia zone. Glucose uptake was analyzed by PET/CT. RAGE, MMP9 and inflammatory factors (COX-2, TNF-α and ICAM-1), HQ-1, HQO-1 and Nrf-2 expression levels in the ischemic brain tissue were analyzed by Immunofluorescence staining and Western blot at 14 days after MCAO. RESULTS: In this study, we have demonstrated that SLI treatment significantly increased the number of brain microvasculature in ipsilateral and glucose uptake in cortex, hippocampus and penumbra in the T1DM + MCAO rats. SLI also significantly decreased the expression of RAGE, MMP9 and inflammatory factors expression, and increased the expression of HQ-1, HQO-1 and Nrf-2 in T1DM + MCAO rats. CONCLUSION: The study showed that SLI could protect against cerebral ischemia injury in T1DM + MCAO rats and the mechanism is related to decrease inflammatory factors and activate of the Nrf2/HO-1 signaling pathway.
format Online
Article
Text
id pubmed-5424323
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54243232017-05-10 Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats Wang, Fujiang He, Qiansong Wang, Jinxin Yuan, Qing Guo, Hong Chai, Lijuan Wang, Shaoxia Hu, Limin Zhang, Yue BMC Complement Altern Med Research Article BACKGROUND: Salvianolate lyophilized injection (SLI) has been clinically used in China for the treatment of acutely cerebral infarction. Clinical and experimental studies have shown that Diabetes mellitus (DM) not only increases the risk of ischemic stroke recurrence but also leads to poor outcomes and increases fatality rates after stroke. Our previous study has proved that SLI can reduce the infarct volume after stroke in type 1 diabetic rats. The aim of the study is to explore the mechanism of SLI on stroke outcome in type 1 diabetic (T1DM) rats. METHODS: Type 1 diabetes rats model (T1DM) was induced in male Wistar rats by intraperitoneal (i.p) injection of streptozotocin (60 mg/kg) and T1DM rats were subjected to intraluminal middle cerebral artery occlusion (MCAO). The T1DM + MCAO rats were randomly divided into six groups: sham-operated, model-vehicle, positive control group (Edaravone-treating, DE 6 mg/kg) and SLI-treating group (10.5 mg/kg, 21 mg/kg and 42 mg/kg). SLI and DE were administered by tail vein injection at 3 h after MCAO, then daily for 14 days. Micro-CT scans of the brain tissue revealed vessel characteristics and distribution in the ischemia zone. Glucose uptake was analyzed by PET/CT. RAGE, MMP9 and inflammatory factors (COX-2, TNF-α and ICAM-1), HQ-1, HQO-1 and Nrf-2 expression levels in the ischemic brain tissue were analyzed by Immunofluorescence staining and Western blot at 14 days after MCAO. RESULTS: In this study, we have demonstrated that SLI treatment significantly increased the number of brain microvasculature in ipsilateral and glucose uptake in cortex, hippocampus and penumbra in the T1DM + MCAO rats. SLI also significantly decreased the expression of RAGE, MMP9 and inflammatory factors expression, and increased the expression of HQ-1, HQO-1 and Nrf-2 in T1DM + MCAO rats. CONCLUSION: The study showed that SLI could protect against cerebral ischemia injury in T1DM + MCAO rats and the mechanism is related to decrease inflammatory factors and activate of the Nrf2/HO-1 signaling pathway. BioMed Central 2017-05-10 /pmc/articles/PMC5424323/ /pubmed/28486941 http://dx.doi.org/10.1186/s12906-017-1738-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wang, Fujiang
He, Qiansong
Wang, Jinxin
Yuan, Qing
Guo, Hong
Chai, Lijuan
Wang, Shaoxia
Hu, Limin
Zhang, Yue
Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats
title Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats
title_full Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats
title_fullStr Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats
title_full_unstemmed Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats
title_short Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats
title_sort neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424323/
https://www.ncbi.nlm.nih.gov/pubmed/28486941
http://dx.doi.org/10.1186/s12906-017-1738-8
work_keys_str_mv AT wangfujiang neuroprotectiveeffectofsalvianolatelyophilizedinjectionagainstcerebralischemiaintype1diabeticrats
AT heqiansong neuroprotectiveeffectofsalvianolatelyophilizedinjectionagainstcerebralischemiaintype1diabeticrats
AT wangjinxin neuroprotectiveeffectofsalvianolatelyophilizedinjectionagainstcerebralischemiaintype1diabeticrats
AT yuanqing neuroprotectiveeffectofsalvianolatelyophilizedinjectionagainstcerebralischemiaintype1diabeticrats
AT guohong neuroprotectiveeffectofsalvianolatelyophilizedinjectionagainstcerebralischemiaintype1diabeticrats
AT chailijuan neuroprotectiveeffectofsalvianolatelyophilizedinjectionagainstcerebralischemiaintype1diabeticrats
AT wangshaoxia neuroprotectiveeffectofsalvianolatelyophilizedinjectionagainstcerebralischemiaintype1diabeticrats
AT hulimin neuroprotectiveeffectofsalvianolatelyophilizedinjectionagainstcerebralischemiaintype1diabeticrats
AT zhangyue neuroprotectiveeffectofsalvianolatelyophilizedinjectionagainstcerebralischemiaintype1diabeticrats